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Introduction
Long-term use of antiepileptic drugs (AEDs) renders a pa-
tient more vulnerable to their side effects,
1,2 and the patient 
must then struggle with these side effects in addition to the 
primary disease. Although several studies have shown that 
commonly used AEDs may lead to osteopenia/osteoporosis, 
osteomalacia, and bone fractures,
3,4 there is little information 
available on the effect of oxcarbazepine (OXC) on bone me-
tabolism.
5,6 Mintzer et al.
7 demonstrated that OXC monother-
apy significantly reduced the level of 25-hydroxyvitamin D 
(25-OHD), and changed other bone biomarkers in a pattern 
suggestive of secondary hyperparathyroidism. Although 
OXC is only a limited enzyme inducer, they stated that OXC 
may have some dose-dependent cytochrome P-450 (CYP-450) 
induction properties, or may have an effect on osteoblast pro-
liferation.
It might be possible to avoid the side effects of OXC if the 
underlying mechanisms were known. Several markers, such as 
serum levels of 25-OHD and calcium, and bone mineral den-
sity (BMD), have been used to identify these side effects. The 
present study assessed the effects of OXC monotherapy on 
bone mineralization in terms of the serum levels of parathyroid 
hormone (PTH), alkaline phosphatase (ALP), calcium, phos-
phorus, 25-OHD, osteocalcin, and calcitonin, and the BMD.
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Background and PurposezzThe adverse effects of newer antiepileptic drugs are not well-known. 
This study assessed the impact of oxcarbazepine (OXC) treatment on bone turnover.
MethodszzForty-four children with idiopathic focal (and/or secondarily generalized) epilepsy 
who had been treated with OXC for more than 1 year were compared with 33 healthy, age- and sex-
matched children. Serum calcium, phosphorus, alkaline phosphatase, parathyroid hormone, osteo-
calcin, calcitonin, and 25-hydroxyvitamin D, and bone mineral density were measured to evaluate 
and compare bone mineralization between the two groups.
ResultszzThe serum levels of calcium, osteocalcin, 25-hydroxyvitamin D, and bone mineral densi-
ty did not differ significantly between the study and control groups. However, serum levels of para-
thyroid hormone, alkaline phosphatase, phosphorus, and calcitonin differed significantly between 
the two groups.
ConclusionszzThese findings suggest that OXC treatment leads to secondary hyperparathyroid-
ism with high-turnover bone disease and/or impaired intestinal calcium absorption.
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Methods
This study involved two groups: group 1 comprised 44 children 
aged between 5 and 15 years with idiopathic focal (and/or sec-
ondarily generalized) epilepsy who had been treated with OXC 
as a first-line AED for at least 1 year,
8 while group 2 was the 
control group that comprised 33 healthy, age- and sex-matched 
children. Patients with height and weight measurements below 
the 3rd percentile, using any drug that may affect bone metab-
olism, receiving any other AED, and with chronic illnesses oth-
er than epilepsy were excluded from the study. Serum levels 
of PTH, ALP, calcium, phosphorus, 25-OHD, osteocalcin, and 
calcitonin, and the BMD value were evaluated in both groups 
and statistically compared.
Blood samples were obtained at between 8:00 and 8:30 a.m. 
after an overnight fast. The serum fraction was obtained by 
centrifugation (at 2000×g for 10 min at 4°C) after storing the 
whole blood at room temperature for 1 hour. Serum was stored 
at -80°C until analysis. Serum levels of calcium, phosphorus, 
and ALP were measured spectrophotometrically with an auto-
analyzer using commercial kits (AU-2700, Olympus, Hamburg, 
Germany). The serum level of 25-OHD was determined using 
a high-performance liquid chromatography system with a flu-
orescence detector. Serum levels of PTH, osteocalcin, and cal-
citonin were determined with a chemoluminescence technique 
using an autoanalyzer with commercial kits (Roche E 170, 
Roche Diagnostics, Mannheim, Germany).
BMD was assessed using dual-energy X-ray absorptiome-
try (QDR4500 Elite Hologic, Bedford, MA, USA) in the lum-
bar spine at levels L2-L4. Approval for this study was obtained 
from the Medicine Ethics Committee of Gulhane Military 
Medical Academy Faculty. Informed consent to participate 
was obtained from the parents of all patients.
Statistical methods
All data analysis was performed using the SPSS 11.5 package 
program (SPSS, Chicago, IL, USA). Continuous and categori-
cal variables are expressed as mean±SD values and percentag-
es and frequencies, respectively. Comparisons between groups 
were performed by t-test. The sex distributions for group 1 
(study group) and group 2 (control group) were compared by 
Chi-square test. The level of statistical significance was set at 
p<0.05.
Results
The study group (group 1; n=44) comprised 22 males (50%) 
and 22 females (50%) aged between 5 and 15 years (9.65± 
3.04 years). The control group (group 2; n=33) comprised 17 
males (51%) and 16 females (49%), all healthy, aged between 
5 and 15 years (10.24±2.86 years). The mean duration of OXC 
therapy in group 1 was 16 months (12-23 months). The serum 
levels of PTH, ALP, phosphorous, and calcitonin differed sig-
nificantly between the study and control groups (p=0.003, 
0.011, 0.005, and 0.046, respectively). However, for the serum 
levels of calcium, osteocalcin, and 25-OHD, and the BMD did 
not differ significantly between the two groups. The biochemi-
cal and bone-turnover parameters are presented in Table 1.
Discussion
Several studies have shown that the affect of AEDs on bone 
metabolism may lead to osteopenia/osteoporosis, osteomala-
cia, and bone fractures.
4,9 Hypocalcemia in patients with refrac-
tory epilepsy may lead to osteopenia and osteoporosis that 
could eventually increase the number of bone fractures, which 
makes the follow-up of epileptic patients more difficult.
10 The 
present study detected increased serum levels of PTH, ALP, 
Table 1. Demographic and laboratory findings of the patients 
Study group (mean±standard deviations) Control group (mean±standard deviations ) p
Age (year) 09.65±3.04 10.24±2.860 NS*
Sex (M/F) 022/22 17/16 NS**
Ca (mg/dL) 10.13±0.41 9.95±0.39 0.059*
P (mg/dL) 04.99±0.50 4.62±0.62 0.005*
ALP (U/L) 326±92 274±840 0.011*
PTH (pg/mL) 042.95±10.49 35.70±9.790 0.003*
Calcitonin (pg/mL) 02.16±0.54 2.70±1.42 0.046*
Osteocalcin (ng/mL) 23.68±8.66 21.85±2.670 0.193*
25 Hydroxy Vit D3 (ug/L) 20.23±4.77 21.04±3.700 0.421*
Z score  -0.15±1.14 -0.35±0.920 0.374*
BMD (g/cm²) 00.64±0.25 0.78±0.22 0.419*
*t-test, **Chi-square test. 
ALP: alkaline phosphatase, BMD: bone mineral density, Ca: calcium, M/F: male/female, NS: not significant, P: phosphorus, PTH: para-
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and phosphorous, decreased serum levels of calcitonin, and 
normal levels of calcium in patients with idiopathic focal (and/
or secondarily generalized) epilepsy who had been receiving 
OXC monotherapy as a first-line AED for more than 1 year.
Long-term AED treatment is known to affect bone metabo-
lism.
7 Although the incidence of bone disease due to AEDs 
was reported in the literature to be 19-56%, only 8% of those 
patients had radiologically confirmed rickets.
11 The prevalence 
of osteomalacia in patients receiving long-term AEDs was re-
ported to be 10-30%, while those of hypocalcemia and in-
creased serum levels of ALP were 10-30% and 40%, respec-
tively.
12
Many theories have been proposed to explain the effects of 
AED use in relation to the pathogenesis of bone disease, al-
though the exact mechanism remains to be established.
7 An in-
crease in serum PTH levels associated with AED therapy has 
been reported.
7,13-15 Mintzer et al.
7 suggested that by inducing 
the CYP-450-mediated catabolism of 25-OHD to less biologi-
cally active metabolites, AEDs lead to a decrease in vitamin-
D-mediated bone mineralization and intestinal calcium absorp-
tion. This in turn causes a compensatory increase in PTH, which 
stimulates the production of 1α-hydroxylase, the enzyme re-
sponsible for the conversion of 25-OHD to 1,25-dihydroxyvi-
tamin D (1,25-OHD), which explains the maintenance of 1,25-
OHD levels seen in AED-treated patients.
7 The chronic eleva-
tion of PTH required to maintain 1,25-OHD levels, which is 
referred to as secondary hyperparathyroidism, causes an in-
crease in bone turnover, which leads to long-term loss of bone 
mass. Similarly, Bouillon et al.
15 reported increased PTH lev-
els, low serum 25-OHD levels, and relative hypocalcemia in 
patients receiving anticonvulsant treatment. In the present 
study we found increased serum levels of PTH, ALP, and phos-
phorous, decreased calcitonin levels, and normal serum 25-
OHD and calcium levels, which may also be referred to as sec-
ondary hyperparathyroidism. In secondary hyperparathyro-
idism, serum calcium levels are often maintained within the 
normal range and ALP levels are elevated, which is thought to 
be related to compensatory stimulation of osteoblastic activity 
in bone.
16
ALP measurement is an adjunct test for assessing high bone 
turnover.
17 High ALP levels are generally related to liver or 
bone disease, which can be differentiated by a concurrent in-
crease in liver function tests or bone biochemical parameters. 
The normal liver function tests in the present study suggested 
to us that high ALP levels are more suggestive of bone disease 
than liver disease. Verrotti et al.
18 reported increased bone-turn-
over markers independent of vitamin D deficiency in patients 
receiving AEDs. Another study found normal serum levels of 
vitamin D metabolites, and bone biopsies revealing increased 
osteoid formation but normal calcification, accelerated miner-
alization rate, and decreased mineralization lag time (indica-
tive of increased bone turnover) in patients receiving long-
term AED therapy.
14 Therefore, OXC might have effects on 
osteoblastic activity, osteoid formation, and calcification, al-
though osteoblasts may synthesize sufficient osteoid while 
mineralization may be deficient.
Another suggested mechanism is the ineffective absorption 
of fat-soluble vitamin D and/or impaired intestinal calcium 
absorption. In a study of rats that examined the effects of AEDs 
on intestinal calcium transport, rats treated with phenytoin had 
markedly decreased calcium absorption.
19 OXC may thus have 
interfered with intestinal calcium absorption in the patients in 
the present study. The other proposed mechanism is calcitonin 
deficiency. Calcitonin is a hormone that is produced by the 
thyroid gland and inhibits osteoclast-mediated bone resorp-
tion. In an in vitro study by Vernillo et al.,
20 calcitonin secre-
tion was reduced in osteoblastic rat osteosarcoma cells ex-
posed to phenytoin in the culture media, compared with control 
cells. Thus, calcitonin deficiency may accelerate bone turn-
over, resulting in increased bone resorption.
3 In the present 
study we found a decrease in calcitonin levels that may have 
been associated with OXC treatment.
In conclusion, OXC treatment may cause increased serum 
levels of PTH, ALP, and phosphorous, and decreased levels 
of calcitonin, which may be due to the induction of CYP-450-
mediated catabolism of 25-OHD to less biologically active 
metabolites, or to high-turnover bone disease or impaired in-
testinal calcium absorption. In turn, this may cause a compen-
satory increase in PTH and an increase in bone-turnover mark-
ers. It should be kept in mind that OXC treatment may lead to 
secondary hyperparathyroidism and that such patients should 
be routinely followed-up with regular PTH, ALP, phospho-
rous, and calcitonin blood biochemistry testing.
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